Urolog. pro Praxi, 2007; 8(5): 223-228

Modern pharmacotherapy of Benign Prostatic Hyperplasia

MUDr. Zbyněk Veselský Ph.D

Urocentrum Praha, s.r.o

Benign prostatic hyperplasia (BPH) together with a cataract is the most common non-malignant male diseases that are manager by an invasive procedure. The incidence is not obvious unequivocally due to the existence of different forms of the disease (histologic, asymptomatic – compensated obstruction, symptomatic). It is generally acceptable, that nearly 40 % of men in their forties are affected by some lower urinary tract symptoms. Because there are additional diseases of both sexes (and logically there is no prostate in women) that can cause identical symptoms the term lower urinary tract symptoms (LUTS) was introduced. In case of prostatic obstruction accurate terminology is LUTS/BHP (Coffey). Diagnostic workup is quite undemanding, however differential diagnosis is unbelievably broad. It is true that basis examination includes digital rectal exam, appropriate diagnosis (including a specific questionnaire) and urine analysis to rule out infection. Prostate specific antigen (PSA) level is important in patients perspective for a therapy of possibly diagnosed prostate cancer. Most units have the ability to quantify urinary flow by means of uroflowmetry (UFM) having in mind the limits of urine volume and data as such.

Keywords: benign prostatic hyperplasia, pharmacotherapy, indication

Published: October 23, 2007  Show citation